Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation

Table 1 Effectiveness of lamivudine treatment and frequency of YMDD mutant occurrence after lamivudine treatment in chronic hepatitis B patients: with proper renal function, undergoing dialysis and after kidney transplantation.

Patients	n	Elimination of HBV-DNA (%)	Elimination of HBeAg (%)	Appearance of YMDD (%)	Normalization of ALT activity (%)
Normal liver function	68	36 (53)	35 (51)	912 (13)	53 (79)
Dialysis	16	9 (56)	6 (38)	0 (0)	15 (94)
After kidney transplantation	7	1 (14)	3 (43)	2 (29)	7 (100)

¹P<0.02, χ² test with Yates’s correction,

²P<0.006, χ² test with Yates’s correction.

Table 2 Mean of selected biochemical parameters before and 12 mo after the end of lamivudine treatment.

	Normal renal function		Dialysis		After kidney transplantation
	1	2	1	2	1	2
Erythrocytes (×106/mL)	4.444	4.381	3.633	3.597	4.139	3.966
Platelets (×103/mL)	150	149	159	148	166	197
Leucocytes (×103/mL)	5.75	5.44	5.8	6.5	7.2	82
Hemoglobin (mg/dL)	14.6	14.7	11.4	11.2	13.6	13
Bilirubin (mg/dL)	2	1.21	0.66	0.45	0.85	0.72
Total protein (g/L)	7.1	7.2	7.1	7	6.9	7.1
Albumin (g/L)	3.75	4.2	3.68	3.78	3.81	3.82
Urea (mg/dL)	30	30	140	137	51	49
Creatine (mg/dL)	0.89	0.91	8.05	7.96	1.84	1.99

1 – Before therapy, 2 – After 12 mo treatment.